Etiologic Studies in the PLCO Trial

PLCO 试验中的病因学研究

• 批准号: 7288891
• 负责人: Richard S Hayes
• 金额: --
• 依托单位: DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7288891
• 关键词: Etiologic; Studies; PLCO; Trial

The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial is a large randomized trial to determine if screening for these cancers reduces mortality. The Trial is carried out by the NCI under contract with investigators at ten clinical centers in the United States. The study includes approximately 155,000 volunteers (recruited from 1993 through 2001, ages 55-74, equally distributed to the screening and control arms of the Trial). The PLCO Etiology and Early Markers Study (EEMS) supports etiologic and early detection studies of cancers and other conditions. EEMS uses data and samples collected in the context of the PLCO Trial including: 1. Baseline demographic and risk factor information on all participants,2. Food Frequency Questionnaires(FFQ) on all participants3. Fractionated blood specimens at each of six screening rounds from screened participants,4. Buccal cell samples from control participants, and5. Information on all-cancer incidence and selected other medical conditions. The PLCO EEMS is a national resource, actively managed by the NCI and directed towards meeting the Institutes strategic priorities in molecular epidemiology and early detection, in collaboration with Christine Berg, MD, Project Officer, PLCO Trial and Phil Prorok, PhD, Chief Statistician, PLCO Trial. The NCI maintains follow-up of cohort members and a PLCO EEMS research database and sample inventory, and initiates additional risk factor and biologic materials collection, including collection of pathologic material. In addition, in conjunction with research activities in PLCO EEMS, NCI investigators develop added-value resources, including validation of biochemical and cytogenetic markers, tissue arrays for pathologic samples (in planning), nutritional modules for FFQs, and assays for genetic analysis (http://snp500cancer.nci.nih.gov). NCI scientists, study center investigators and others use these resources to address important issues in clarifying the etiology of cancers and in the development of effective early markers of the disease. Multi-investigator studies of determinants of colorectal adenoma (Cas ID: 00040) and prostate cancer (Cas ID: 10003) are underway. Other investigations include determinants of tobacco use, risk factors for benign prostatic hyperplasia, and protein early detection markers for cancer.

前列腺，肺，结直肠癌和卵巢癌（PLCO）筛查试验是一项大型随机试验，以确定这些癌症的筛查是否会降低死亡率。该试验由NCI与美国十个临床中心的调查人员合同进行。该研究包括大约155,000名志愿者（从1993年到2001年，年龄在55-74岁之间招募，同样分布在试验的筛查和控制臂上）。 PLCO病因和早期标记研究（EEMS）支持癌症和其他疾病的病因学和早期检测研究。 EEMS使用在PLCO试验中收集的数据和样本，包括： 1。所有参与者的基线人口统计和风险因素信息，2。所有参与者的食品频率问卷（FFQ）3。筛选参与者的六个筛查回合中的每一个，4。来自对照参与者的颊细胞样品和5。有关全癌发病率并选择其他医疗状况的信息。 PLCO EEMS是一种国家资源，由NCI积极管理，并致力于与分子流行病学和早期检测机构的战略优先事项，并与PLCO试验项目官员Christine Berg合作，PLCO审判和Ph. Phil Prorok，Plco Ploco首席统计学家PLCO试验。 NCI维护了队列成员和PLCO EEMS研究数据库和样本清单的后续行动，并启动了其他风险因素和生物材料收集，包括病理材料的收集。此外，与PLCO EEMS中的研究活动结合在一起，NCI研究者开发了附加的值资源，包括对生化和细胞遗传学标记的验证，病理样本的组织阵列（计划），FFQS的营养模块以及用于遗传分析的分析（HTTP://snp500cancancancancancancancancancesn.nc）。 NCI科学家，研究中心的研究人员和其他人使用这些资源来解决重要的问题，以阐明癌症的病因和开发有效的疾病早期标志。 进行结直肠腺瘤决定因素（CAS ID：00040）和前列腺癌（CAS ID：10003）的多侵袭者研究正在进行中。其他研究包括烟草使用的决定因素，良性前列腺增生的危险因素和蛋白质的早期检测标志物。